Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | RAB9A | P51151 | 5/20 | 0.75 |
| ▸ | NPC1 | O15118 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 2/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13030714 | 1.00 | CYP1A2 (0.81) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL13270534 | 1.00 | CYP1A2 (0.81) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL24119203 | 0.90 | CYP1A2 (1.00) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL2208124 | 0.90 | CYP1A2 (1.00) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL2208129 | 0.90 | CYP1A2 (1.00) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL28865784 | 0.86 | ALDH1A1 (1.00) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL23251385 | 0.81 | MAPT (0.81) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL29419236 | 0.80 | MAPT (1.00) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL782731 | 0.80 | MAPT (1.00) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 | |
| SCHEMBL805340 | 0.80 | MAPT (1.00) | CYP1A2CYP2C19ALDH1A1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| EP-1265866-B1 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-07-21 | — | — | EP | disclosed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-02-24 | — | — | US | disclosed |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. | 2004-09-30 | — | — | US | disclosed |
| US-6737418-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | EURO-CELTIQUE S.A. (LU) | 2004-05-18 | — | — | US | disclosed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | disclosed |
| EP-1265866-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-12-18 | — | — | EP | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | PURDUE PHARMA L.P. | 2002-04-04 | — | — | US | disclosed |
| WO-2001068612-A2 | ARYL SUBSTITUTED PYRIDINES, PYRIMIDINES, PYRAZINES AND TRIAZINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, CACNA1C, KYNU | CYP1A2 459/4885CYP2C19 2407/4885ALDH1A1 226/4885 |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | CYP1A2 1244/4885CYP2C19 1216/4885ALDH1A1 284/4885 |
| US-20040192691-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | CYP1A2 981/4885CYP2C19 3050/4885ALDH1A1 205/4885 |
| US-20020040025-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, KYNU, CACNA1C | CYP1A2 981/4885CYP2C19 3050/4885ALDH1A1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.